Is loratadine (Claritin) safe to use during the first trimester at 8 weeks of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Loratadine (Claritin) is Safe at 8 Weeks Pregnancy

Loratadine is safe to use at 8 weeks of pregnancy and does not increase the risk of major congenital malformations. The evidence consistently supports its use during the first trimester, including the critical period of organogenesis at 8 weeks.

Evidence Supporting Safety

The most comprehensive guideline evidence comes from the 2008 Journal of Allergy and Clinical Immunology practice parameter, which explicitly states that "the safety of second-generation antihistamines used during the first trimester of pregnancy has now been confirmed through large birth registries, case-control studies, and cohort studies" 1. Specifically, loratadine and cetirizine are classified as U.S. FDA Pregnancy Category B drugs, meaning there is no evidence of harm to the fetus during pregnancy 2.

Key Research Findings

The strongest research evidence includes:

  • A multicenter prospective study of 161 loratadine-exposed pregnancies found no significant difference in malformation rates (5 malformations in exposed group vs. 6 in controls, P=0.9), with similar live birth rates, gestational age, and birth weights 3

  • An Israeli prospective controlled cohort of 210 loratadine-exposed pregnancies (77.9% in first trimester) showed a malformation rate of only 2.3% compared to 3.0% in controls, with no statistical difference 4

  • A 2005 critical review documented over 2,147 women exposed to loratadine during pregnancy with no increased risk of major congenital malformations 5

Clinical Recommendation

Use loratadine at standard dosing (10 mg daily) without hesitation at 8 weeks of pregnancy. While older guidelines from 2007 suggested avoiding all antihistamines in the first trimester as a general precaution 2, this recommendation has been superseded by substantial human safety data accumulated since then.

Important Considerations

  • First-generation antihistamines like chlorpheniramine were historically preferred due to their "long safety record," but their sedating effects make them less desirable 1

  • Hydroxyzine should be avoided during early pregnancy based on animal data and manufacturer contraindications 2, 1

  • Diphenhydramine has some concern regarding a possible association with cleft palate, though recent studies have not confirmed increased risk 1

Practical Guidance

The FDA drug label for Claritin states: "If pregnant or breast-feeding, ask a health professional before use" 6. However, this conservative labeling does not reflect the robust human safety data. Given the accumulated evidence from multiple large studies and registries, loratadine can be recommended confidently at 8 weeks of pregnancy.

Avoid oral decongestants (like pseudoephedrine or phenylephrine) during the first trimester, as these have conflicting reports of associations with gastroschisis and small intestinal atresia 1.

If additional allergy treatment is needed beyond loratadine, intranasal corticosteroids (particularly budesonide, fluticasone, or mometasone) are also safe options during pregnancy 1, 7, 8.

References

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Research

Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study.

The Journal of allergy and clinical immunology, 2003

Research

Safety of intranasal corticosteroid sprays during pregnancy: an updated review.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.